Assenagon Asset Management S.A.

Position in CGEM — Cullinan Therapeutics, Inc.

CIK 1546007 SENNINGERBERG, N4

Position in CGEM

as of Jun 30, 2026 · filed Aug 21, 2026 Compact

Position Value

$1,123,229

-$847,769 QoQ

Shares Held

61,682

-55.5% QoQ

Ownership

0.096%

of shares outstanding

% of Portfolio

0.00%

of 13F equity value

Holder Rank

#77

of 183 holders

Holding Since

Dec 2022

13 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Jun 30, 2026

Assenagon Asset Management S.A. holds $1,940,218,245 across 69 Biotechnology names. CGEM ranks #47 (0.1% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	VRTX	Vertex Pharmaceuticals Inc / Ma	759,564	$377,298,225
2	ROIV	Roivant Sciences Ltd.	8,362,952	$295,964,871
3	REGN	Regeneron Pharmaceuticals, Inc.	244,927	$152,721,781
4	AXSM	Axsome Therapeutics, Inc.	454,682	$111,292,513
5	BMRN	Biomarin Pharmaceutical Inc	1,762,086	$100,826,560
6	HALO	Halozyme Therapeutics, Inc.	997,643	$78,085,517
7	MDGL	Madrigal Pharmaceuticals, Inc.	124,214	$66,696,707
8	TARS	Tarsus Pharmaceuticals, Inc.	947,495	$59,635,335

13 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$1,123,229	61,682	-55.5%	Shares	Sole	2026-08-21
2026-03-31	$1,970,998	138,705	-12.6%	Shares	Sole	2026-04-20
2025-12-31	$1,643,093	158,753	-10.7%	Shares	Sole	2026-01-09
2025-09-30	$1,053,672	177,685	+1665.9%	Shares	Sole	2025-10-07
2025-06-30	$75,766	10,062	0.0%	Shares	Sole	2025-07-11
2025-03-31	$76,169	10,062	-92.4%	Shares	Sole	2025-04-15
2024-12-31	$1,623,106	133,260	-1.3%	Shares	Sole	2025-01-14
2024-09-30	$2,260,502	135,036	+18.3%	Shares	Sole	2024-10-23
2024-06-30	$1,991,560	114,195	-81.3%	Shares	Sole	2024-07-18
2023-09-30	$5,512,409	609,106	+380.1%	Shares	Sole	2023-11-06
2023-06-30	$1,365,142	126,872	-42.7%	Shares	Sole	2023-07-25
2023-03-31	$2,264,308	221,340	+166.6%	Shares	Sole	2023-04-18
2022-12-31	$875,755	83,010	—	Shares	Sole	2023-01-12
No filing history on record for this holder in this stock.